Pharma feed

  • AbbVie Inc
  • Events
  • Social Updates
  • Twitter
N
GlaxoSmithKline PLC
Fairfieldcurrent· 19 Aug 2018

GlaxoSmithKline (GSK) Releases Earnings Results

GlaxoSmithKline (LON:GSK) released its quarterly earnings data on Wednesday, July 25th. The company reported GBX 52.70 ($0.67) EPS for the quarter, Bloomberg Earnings reports. GlaxoSmithKline had a net margin of 9.36% and a return on equity of 348.10%.

  • GlaxoSmithKline PLC
  • Financial & Business Performance
  • News Articles
  • News and Other Websites
N
Merck & Co., Inc.
Fairfieldcurrent· 19 Aug 2018

Merck & Co., Inc. (NYSE:MRK) Releases FY18 Earnings Guidance

Merck & Co., Inc. (NYSE:MRK) issued an update on its FY18 earnings guidance on Friday morning. The company provided EPS guidance of $4.22-4.30 for the period, compared to the Thomson Reuters consensus EPS estimate of $4.24.

  • Merck & Co., Inc.
  • Financial & Business Performance
  • News Articles
  • News and Other Websites
N
Bayer AG
Cmferesearch· 19 Aug 2018

BASF completes acquisition of vegetable seeds business from Bayer

Saif currently works as a content writer for CMFE Research, AlgosOnline and a couple of other platforms. A Computer Science graduate who has a zest for writing over coding, commenced his journey in the writing industry as a freelancer.

  • saif corporation
  • Bayer AG
  • M&A Activities
  • News Articles
  • News and Other Websites
N
Celgene Corp
Fairfieldcurrent· 19 Aug 2018

Celgene (CELG) Posts Earnings Results, Beats Expectations By $0.05 EPS

Celgene (NASDAQ:CELG) posted its quarterly earnings data on Thursday, July 26th. The biopharmaceutical company reported $2.16 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $2.11 by $0.05, Bloomberg Earnings reports. Celgene had a return on equity of 87.28% and a net margin of 19.81%.

  • Celgene Corp
  • Financial & Business Performance
  • News Articles
  • News and Other Websites
N
AstraZeneca PLC
Baseballdailydigest· 19 Aug 2018

AstraZeneca plc (AZN) to Issue GBX 68.40 Dividend

AstraZeneca plc (LON:AZN) declared a dividend on Thursday, July 26th, Upcoming.Co.Uk reports. Shareholders of record on Thursday, August 9th will be paid a dividend of GBX 68.40 ($0.87) per share by the biopharmaceutical company on Monday, September 10th.

  • AstraZeneca PLC
  • Financial & Business Performance
  • News Articles
  • News and Other Websites
N
Bristol-Myers Squibb Co
Steeleherald· 19 Aug 2018

$5.65 Billion in Sales Expected for Bristol-Myers Squibb Co (BMY) This Quarter – Steele Hereald

Equities research analysts expect that Bristol-Myers Squibb Co (NYSE:BMY) will post sales of $5.65 billion for the current quarter, according to Zacks. Four analysts have issued estimates for Bristol-Myers Squibb’s earnings, with the highest sales estimate coming in at $5.71 billion and the lowest estimate coming in at $5.58 billion.

  • Bristol-Myers Squibb Co
  • Financial & Business Performance
  • News Articles
  • News and Other Websites
N
GlaxoSmithKline PLC
Infosurhoy· 18 Aug 2018

Sligo to suffer loss of 165 jobs as GlaxoSmithKline closes manufacturing plant – Ireland

Sligo is to suffer the loss of 165 jobs in the next three years as GlaxoSmithKline closes its manufacturing plant there. The company told employees at Stiefel Laboratories of its proposal to phase down production at the skincare manufacturing site.

  • GlaxoSmithKline PLC
  • Stiefel Laboratories Inc
  • Cost Cutting
  • News Articles
  • News and Other Websites
N
Gild
Baseballdailydigest· 18 Aug 2018

Gilead Sciences (GILD) Issues Earnings Results, Beats Estimates By $0.35 EPS

Gilead Sciences (NASDAQ:GILD) issued its quarterly earnings data on Wednesday, July 25th. The biopharmaceutical company reported $1.91 EPS for the quarter, topping the consensus estimate of $1.56 by $0.35, Bloomberg Earnings reports. Gilead Sciences had a return on equity of 41.57% and a net margin of 9.52%.

  • Gild
  • Gilead Sciences, Inc.
  • Financial & Business Performance
  • News Articles
  • News and Other Websites
N
Bayer AG
Readingeagle· 18 Aug 2018

Bayer vows stronger roundup defense as it absorbs Monsanto

Saturday August 18, 2018 11:19 AM Bayer acquired Monsanto Co. for $66 billion in June. Bayer vowed to step up its defense against a wave of U.S. lawsuits over the herbicide Roundup as it began the formal integration of Monsanto Co., acquired for $66 billion in June.

  • Bayer AG
  • Monsanto Company
  • Regulatory & Legal
  • News Articles
  • News and Other Websites
Twitter· 18 Aug 2018

#ICYMI: In June, “Zac’s Play Day,” an illustrated children’s book about SMA, won an award at the 2018 Cannes Lions Festival for patient engagement. Learn more about Zac here: http://bit.ly/2ztDPgE #SMAMonth

Spinal Muscular Atrophy
You are now leaving TogetherinSMA.com This link will take you to a website that is outside the control of Biogen. Links are provided as a courtesy for informational purposes only.
  • Biogen Inc
  • Cannes Lions International Festival
  • Events
  • Awards & Recognitions
  • Social Updates
  • Twitter
N
Zoetis Inc
Fairfieldcurrent· 18 Aug 2018

Zoetis (NYSE:ZTS) Announces Quarterly Earnings Results

Zoetis (NYSE:ZTS) announced its earnings results on Thursday, August 2nd. The company reported $0.77 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.71 by $0.06, Bloomberg Earnings reports. Zoetis had a return on equity of 72.30% and a net margin of 19.95%.

  • Zoetis Inc
  • Financial & Business Performance
  • News Articles
  • News and Other Websites
N
Merck & Co., Inc.
Patientdaily· 18 Aug 2018

MERCK: Healthy Interactions and Merck Announce Launch of Digital Health Platform Designed to Enhance Patient Engagement in Diabetes Management

Merck issued the following announcement on Aug. 17. Healthy Interactions, a global leader in health education, in collaboration with Merck (NYSE : MRK ), known as MSD outside the United States and Canada, announced the launch of map4health™ – a digital platform and mobile application in the U.S.

  • Merck & Co., Inc.
  • Interactions Corporation
  • Partnerships & Alliances
  • New Offerings
  • News Articles
  • News and Other Websites
N
Alexion Pharmaceuticals Inc
Baseballdailydigest· 18 Aug 2018

Alexion Pharmaceuticals (NASDAQ:ALXN) Releases FY18 Earnings Guidance

Alexion Pharmaceuticals (NASDAQ:ALXN) issued an update on its FY18 earnings guidance on Thursday morning. The company provided earnings per share guidance of $7.00-7.15 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $7.02.

  • Alexion Pharmaceuticals Inc
  • Financial & Business Performance
  • News Articles
  • News and Other Websites
N
Bayer AG
Laht· 18 Aug 2018

Bayer Rejects Media Report of Fresh Dicamba Lawsuits

Bayer Rejects Media Report of Fresh Dicamba Lawsuits MADRID – Bayer AG on Friday rejected a report by German magazine WirtschaftsWoche, which claimed that farmers in the US had filed class-action lawsuits related to the Monsanto-produced Dicamba herbicide.

  • Bayer AG
  • Regulatory & Legal
  • News Articles
  • News and Other Websites
Novo Nordisk AS
Novonordisk· 18 Aug 2018

Novo Nordisk acquires Ziylo Ltd to accelerate its development of glucose responsive insulins

Novo Nordisk acquires Ziylo Ltd to accelerate its development of glucose responsive insulins Novo Nordisk gains full rights to Ziylo's early-stage glucose binding molecules in a staged acquisition with a potential deal value that could

  • Novo Nordisk AS
  • M&A Activities
  • Company Websites
Twitter· 18 Aug 2018

Healthy Interactions, Merck launches digital diabetes management, engagement platform https://t.co/Irvmb3R3xB #AADE18 #Engage4Health

Healthy Interactions, Merck launch digital diabetes management, engagement platform
Healthy Interactions, a population health company that offers both digital and in-person programs for chronic disease management and education, and Merck have launched a diabete...
  • Interactions Corporation
  • Merck & Co., Inc.
  • MobiHealthNews
  • New Offerings
  • Social Updates
  • Twitter
Twitter· 18 Aug 2018

As a result of our DREAMS partnership with @PEPFAR, 65% of the highest #HIV-burdened African communities in the program achieved 25% or greater decline in new HIV diagnoses in women 15-24 years old: https://bit.ly/2jIAwYr .

Year In Review 2017
Gilead’s 2017 Year in Review provides an in-depth look at our efforts to advance treatments for people living with some of the world’s most serious diseases in a way that is soc...
  • Gilead Sciences, Inc.
  • Partnerships & Alliances
  • Social Updates
  • Twitter
N
Zoetis Inc
Zoetis· 18 Aug 2018

Zoetis to Participate in the William Blair 2018 Growth Stock Conference

PARSIPPANY, N.J.--(BUSINESS WIRE)--Zoetis Inc. (NYSE:ZTS) will participate in the William Blair 2018 Growth Stock Conference on Tuesday, June 12, 2018, in Chicago, Ill. Juan Ramón Alaix, Chief Executive Officer, will represent the company and respond to questions from analysts.

  • William Blair & Co LLC
  • Zoetis Inc
  • Events
  • News Articles
  • News and Other Websites
N
Zoetis Inc
Zoetis· 18 Aug 2018

Zoetis to Acquire Abaxis, a Leading Global Provider of Veterinary Point-of-Care Diagnostic Instruments

PARSIPPANY, N.J. and UNION CITY, Calif.--(BUSINESS WIRE)--Zoetis Inc. (NYSE:ZTS) and Abaxis, Inc. (NASDAQ:ABAX) today announced a definitive merger agreement pursuant to which Zoetis will acquire Abaxis, a leader in the development, manufacture and marketing of diagnostic instruments for veterinary point-of-care services for US $83 per share in cash, or approximately $2.0 billion in aggregate.

  • Zoetis Inc
  • Abaxis Inc
  • M&A Activities
  • News Articles
  • News and Other Websites
N
Bayer AG
Infosurhoy· 18 Aug 2018

Bayer begins with Monsanto integration after finalizing merger

BERLIN, Aug. 16 (Xinhua) — German multinational pharmaceutical and life sciences company Bayer AG officially completed its acquisition of Monsanto on Thursday by fulfilling all requirements set by antitrust regulators in the 63-billion-euro (72-billion-U.S.-dollar) agrochemical industry merger.

  • Bayer AG
  • Monsanto Company
  • M&A Activities
  • Regulatory & Legal
  • News Articles
  • News and Other Websites
N
Johnson & Johnson
Seeking Alpha· 18 Aug 2018

Trump Insurance For Johnson & Johnson

I close with a brief discussion of a source of ideas for JNJ longs looking to exit. In light of the additional litigation risk, I present a couple of updated hedges for JNJ longs. I also discuss the implication of JNJ's low hedging costs.

  • Johnson & Johnson
  • Regulatory & Legal
  • News Articles
  • News and Other Websites
N
Bayer AG
Koel· 18 Aug 2018

BASF Closes Acquisition of Bayer's Vegetable Seeds Business

Privacy Policy (Updated: 5/18/18) Townsquare Media, Inc. and its subsidiaries and affiliates (individually or collectively, “TSM” or “we/our/us”) respect your privacy and are committed to protecting it through our compliance with this policy. This policy describes the type of information we may collect from you and or that you may provide us when you interact with our websites, mobile applications, email, and online services, participate in our loyalty program, or register for one of our events (our “Services”).

  • Bayer AG
  • M&A Activities
  • News Articles
  • News and Other Websites
N
Pfizer Inc.
Endpts· 17 Aug 2018

Pfizer spells out PhIII talazoparib data in NEJM article; Tolero teams up with AbbVie for AML combo

→ David Hung offered a hard sell of his experimental PARP drug talazoparib while bidders lined up in what turned out as a $14 billion Medivation buyout by Pfizer. Now researchers are spelling out all the data in an article in the New England Journal of Medicine as Pfizer lines up a quick review and likely OK for a drug that will face some well entrenched competitors.

  • Pfizer Inc.
  • Partnerships & Alliances
  • News Articles
  • News and Other Websites
N
Merck & Co., Inc.
Brinkwire· 17 Aug 2018

FDA approves Bristol-Myers’ Opdivo for small cell lung… – Brinkwire

Aug 17 – Bristol-Myers Squibb Co said on Friday the U.S. Food and Drug Administration approved its treatment, Opdivo, for patients whose lung cancer had progressed even after undergoing chemotherapy and at least one other therapy.

  • Merck & Co., Inc.
  • Bristol-Myers Squibb Co
  • Regulatory & Legal
  • News Articles
  • News and Other Websites
1 2 3 4 5